Quick Summary
- Investment Amount: Agomab Therapeutics raised $89 million in Series D financing.
- Key Backers: Led by new investors Sanofi and Invus, with participation from existing investors.
- Therapy Focus: Targeting fibrosis with organ-specific treatments for the liver, lungs, and intestines.
- Clinical Pipeline:
- AGMB-129: For fibrostenosing Crohn’s disease, with Phase 2a results expected in 2025.
- AGMB-447: For idiopathic pulmonary fibrosis, in early-stage trials.
- AGMB-101: For liver cirrhosis, nearing IND submission.
Agomab Therapeutics, a biotech company specializing in fibrosis treatments, has announced an $89 million Series D funding round, supported by new investors Sanofi and Invus, alongside previous backers. This financing enables Agomab to move forward with several promising therapies designed to treat fibrosis by targeting specific organs affected by the condition.
What This Funding Will Support
Fibrostenosing Crohn’s Disease (AGMB-129)
Agomab’s lead candidate, AGMB-129, targets fibrosis in patients with fibrostenosing Crohn’s disease, which causes scar tissue buildup in the intestines, leading to narrowing and obstruction. This drug, delivered orally, works by inhibiting ALK5—a receptor involved in the TGF-β pathway that plays a role in fibrosis. Currently in Phase 2a trials, AGMB-129 has the potential to provide a targeted treatment for Crohn’s patients who suffer from intestinal strictures. Preliminary data is expected in early 2025.Idiopathic Pulmonary Fibrosis (AGMB-447)
AGMB-447 is an inhaled therapy for idiopathic pulmonary fibrosis (IPF), a progressive lung disease with few effective treatments. This therapy aims to deliver the fibrosis-fighting agent directly to the lungs, minimizing systemic side effects. Currently in Phase 1 trials, AGMB-447 could help slow disease progression and improve quality of life for IPF patients.Liver Cirrhosis (AGMB-101)
AGMB-101 is a MET agonist antibody, targeting liver cirrhosis by stimulating the regenerative capabilities of the liver. Currently in the final preclinical stages, AGMB-101’s mechanism aims to reverse liver damage caused by fibrosis, potentially delaying or avoiding the need for liver transplants. IND (Investigational New Drug) submission is anticipated soon.
Industry and Investor Confidence
This funding round signals a strong endorsement of Agomab’s focus on organ-specific fibrosis therapies. With Sanofi and Invus joining, the company benefits from both financial support and strategic guidance, reflecting the larger industry shift toward targeted treatments that directly address fibrotic diseases’ root causes. Tim Knotnerus, CEO of Agomab, shared that the new funding “validates our work and commitment to advancing innovative solutions for fibrosis.”
Fibrosis treatment is a challenging area with high unmet needs, as these diseases often involve chronic tissue scarring, leading to progressive organ dysfunction. By focusing on validated pathways, Agomab hopes to create safer, effective treatment options with fewer side effects, addressing a significant gap in current therapies for conditions like Crohn’s disease, IPF, and liver cirrhosis.
Looking Ahead
With funding secured, Agomab is positioned to accelerate its trials, with key data anticipated in 2025. If successful, these therapies could offer hope to patients whose options are limited by existing treatments.
References
